 |
50 Diseases |  |
65 Trials |
|
65 Trials |  |
4287 News |  |
| «12...38394041424344454647484950» |
- | pacmilimab (CX-072) / CytomX
New P1/2 trial, Combination therapy, Monotherapy, Metastases: PROCLAIM-072 : PROCLAIM-CX-072: A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas (clinicaltrials.gov) - Jan 5, 2017
P1/2, N=150, Not yet recruiting, Sponsor: CytomX Therapeutics
- Cotellic (cobimetinib) / Exelixis, Roche, Zelboraf (vemurafenib) / Roche, Tecentriq (atezolizumab) / Roche
Enrollment open, PD(L)-1 Biomarker, IO biomarker, Metastases: ImmunoCobiVem: Evaluating the Efficacy and Safety of a Sequencing Schedule of Cobimetinib Plus Vemurafenib Followed by Immunotherapy With an Anti- PD-L1 Antibody in Patients With Unresectable or Metastatic BRAF V600 Mutant Melanoma (clinicaltrials.gov) - Dec 22, 2016
P2, N=176, Recruiting, Sponsor: University Hospital, Essen
Not yet recruiting --> Recruiting
- || Zelboraf (vemurafenib) / Roche
Trial primary completion date: Vemurafenib in Children With Recurrent/Refractory BRAF Gene V600E (BRAFV600E)-Mutant Gliomas (clinicaltrials.gov) - Nov 23, 2016
P0, N=54, Recruiting, Sponsor: Theodore Nicolaides MD
Not yet recruiting --> Recruiting Trial primary completion date: Jan 2017 --> Jan 2018
- || Zelboraf (vemurafenib) / Roche
Trial primary completion date, Metastases: An Open-Label Study of Zelboraf (Vemurafenib) in Patients With Braf V600 Mutation Positive Metastatic Melanoma (clinicaltrials.gov) - Nov 8, 2016
P4, N=60, Active, not recruiting, Sponsor: Hoffmann-La Roche
Trial primary completion date: Jan 2017 --> Jan 2018 Trial primary completion date: Jun 2015 --> Dec 2018
- Zelboraf (vemurafenib) / Roche
Trial primary completion date: Vemurafenib With Lymphodepletion Plus Adoptive Cell Transfer & High Dose IL-2 Metastatic Melanoma (clinicaltrials.gov) - Oct 26, 2016
P2, N=30, Recruiting, Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Trial primary completion date: Jun 2015 --> Dec 2018 Trial primary completion date: Dec 2016 --> Jun 2017
- Zelboraf (vemurafenib) / Roche, XL888 / Exelixis, Merck (MSD)
Trial primary completion date: Study of XL888 With Vemurafenib for Patients With Unresectable BRAF Mutated Stage III/IV Melanoma (clinicaltrials.gov) - Oct 26, 2016
P1, N=21, Active, not recruiting, Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Trial primary completion date: Dec 2016 --> Jun 2017 Trial primary completion date: Dec 2016 --> Sep 2016
- |||| Cotellic (cobimetinib) / Exelixis, Roche, Zelboraf (vemurafenib) / Roche, Tecentriq (atezolizumab) / Roche
Trial primary completion date, PD(L)-1 Biomarker, Metastases: IMspire150: A Study of Atezolizumab Plus Cobimetinib and Vemurafenib Versus Placebo Plus Cobimetinib and Vemurafenib in Previously Untreated BRAFv600 Mutation-Positive Patients With Metastatic or Unresectable Locally Advanced Melanoma (clinicaltrials.gov) - Oct 20, 2016
P3, N=500, Not yet recruiting, Sponsor: Hoffmann-La Roche
Trial primary completion date: Dec 2016 --> Sep 2016 Trial primary completion date: Aug 2024 --> Feb 2020
- |||| Mekinist (trametinib) / Novartis, BeiGene, Tafinlar (dabrafenib) / Novartis, BeiGene
Trial primary completion date, Metastases: COMBI-v: Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma (clinicaltrials.gov) - Oct 20, 2016
P3, N=701, Active, not recruiting, Sponsor: GlaxoSmithKline
Trial primary completion date: Aug 2024 --> Feb 2020 Trial primary completion date: Sep 2018 --> Apr 2014
- || Zelboraf (vemurafenib) / Roche
Trial primary completion date: An Extension (Rollover) Study of Vemurafenib in Participants With BRAF V600 Mutation-Positive Malignancies Previously Enrolled in an Antecedent Vemurafenib Protocol (clinicaltrials.gov) - Oct 11, 2016
P4, N=450, Recruiting, Sponsor: Hoffmann-La Roche
Trial primary completion date: Sep 2018 --> Apr 2014 Trial primary completion date: May 2018 --> Feb 2019
- ||||| Zelboraf (vemurafenib) / Roche
Enrollment closed: BRIM8: A Study of Vemurafenib Adjuvant Therapy in Participants With Surgically Resected Cutaneous BRAF-Mutant Melanoma (clinicaltrials.gov) - Oct 6, 2016
P3, N=503, Active, not recruiting, Sponsor: Hoffmann-La Roche
Trial primary completion date: May 2018 --> Feb 2019 Recruiting --> Active, not recruiting
- || Cotellic (cobimetinib) / Exelixis, Roche, Zelboraf (vemurafenib) / Roche
Trial primary completion date, Metastases: A Study to Detect V-Raf Murine Sarcoma Viral Oncogene Homolog B1 (BRAF) V600 Mutation on Cell-Free Deoxyribonucleic Acid (cfDNA) From Plasma in Participants With Advanced Melanoma (clinicaltrials.gov) - Oct 3, 2016
P2, N=208, Recruiting, Sponsor: Hoffmann-La Roche
Recruiting --> Active, not recruiting Trial primary completion date: Oct 2020 --> May 2021
- Cotellic (cobimetinib) / Exelixis, Roche, Zelboraf (vemurafenib) / Roche
Trial initiation date, Trial primary completion date, Metastases: Radiation Use During Vemurafenib Treatment (clinicaltrials.gov) - Sep 22, 2016
P1, N=36, Not yet recruiting, Sponsor: University of Utah
Trial primary completion date: Oct 2020 --> May 2021 Initiation date: Aug 2016 --> Jan 2017 | Trial primary completion date: Aug 2020 --> Aug 2022
- |||||||||| Cotellic (cobimetinib) / Exelixis, Roche, Zelboraf (vemurafenib) / Roche, Tecentriq (atezolizumab) / Roche
New P3 trial, PD(L)-1 Biomarker, Metastases: IMspire150: A Study of Atezolizumab Plus Cobimetinib and Vemurafenib Versus Placebo Plus Cobimetinib and Vemurafenib in Previously Untreated BRAFv600 Mutation-Positive Patients With Metastatic or Unresectable Locally Advanced Melanoma (clinicaltrials.gov) - Sep 21, 2016
P3, N=500, Not yet recruiting, Sponsor: Hoffmann-La Roche
- Zelboraf (vemurafenib) / Roche
Trial primary completion date, Combination therapy, Metastases: Leflunomide+Vemurafenib in V600 Mutant Met. Melanoma (clinicaltrials.gov) - Sep 15, 2016
P1/2, N=55, Suspended, Sponsor: Massachusetts General Hospital
Initiation date: Aug 2016 --> Jan 2017 | Trial primary completion date: Aug 2020 --> Aug 2022 Trial primary completion date: Jul 2015 --> Jul 2017
- | Cotellic (cobimetinib) / Exelixis, Roche, Zelboraf (vemurafenib) / Roche, Tecentriq (atezolizumab) / Roche
New P2 trial, PD(L)-1 Biomarker, IO biomarker, Metastases: ImmunoCobiVem: Evaluating the Efficacy and Safety of a Sequencing Schedule of Cobimetinib Plus Vemurafenib Followed by Immunotherapy With an Anti- PD-L1 Antibody in Patients With Unresectable or Metastatic BRAF V600 Mutant Melanoma (clinicaltrials.gov) - Sep 15, 2016
P2, N=176, Not yet recruiting, Sponsor: University Hospital, Essen
- || Cotellic (cobimetinib) / Exelixis, Roche, Zelboraf (vemurafenib) / Roche
Trial primary completion date, Metastases: A Study to Detect V-Raf Murine Sarcoma Viral Oncogene Homolog B1 (BRAF) V600 Mutation on Cell-Free Deoxyribonucleic Acid (cfDNA) From Plasma in Participants With Advanced Melanoma (clinicaltrials.gov) - Sep 2, 2016
P2, N=208, Recruiting, Sponsor: Hoffmann-La Roche
Trial primary completion date: Jul 2015 --> Jul 2017 Trial primary completion date: Feb 2019 --> Oct 2020
- Zelboraf (vemurafenib) / Roche
Enrollment closed: BRAF Inhibitor, Vemurafenib, in Patients With Relapsed or Refractory Hairy Cell Leukemia (clinicaltrials.gov) - Aug 19, 2016
P2, N=36, Active, not recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
Trial primary completion date: Feb 2019 --> Oct 2020 Recruiting --> Active, not recruiting
- Cotellic (cobimetinib) / Exelixis, Roche, Zelboraf (vemurafenib) / Roche, XL888 / Exelixis, Merck (MSD)
Enrollment open: XL888 + Vemurafenib + Cobimetinib for Unresectable BRAF Mutated Stage III/IV Melanoma (clinicaltrials.gov) - Aug 12, 2016
P1, N=36, Recruiting, Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- Zelboraf (vemurafenib) / Roche
Trial primary completion date: LOVE: Long-term Outcome After Vemurafenib / BRAF Inhibitors Interruption in Erdheim-chester Disease (clinicaltrials.gov) - Aug 11, 2016
P=N/A, N=20, Recruiting, Sponsor: Groupe Hospitalier Pitie-Salpetriere
Not yet recruiting --> Recruiting Trial primary completion date: Apr 2016 --> Dec 2016
- Cotellic (cobimetinib) / Exelixis, Roche, Zelboraf (vemurafenib) / Roche, onartuzumab (RG3638) / Roche
Trial withdrawal, Combination therapy, Metastases: Safety, Tolerability, and Pharmacokinetics of Onartuzumab Combined With Vemurafenib and/or Cobimetinib in Cancer Patients (clinicaltrials.gov) - Aug 8, 2016
P1, N=0, Withdrawn, Sponsor: Hoffmann-La Roche
Trial primary completion date: Apr 2016 --> Dec 2016 Completed --> Withdrawn
- |||| Braftovi (encorafenib) / Pfizer, Mektovi (binimetinib) / Pfizer
Trial primary completion date, Monotherapy, Metastases: COLUMBUS: Study Comparing Combination of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in BRAF Mutant Melanoma (clinicaltrials.gov) - Jul 28, 2016
P3, N=900, Active, not recruiting, Sponsor: Array BioPharma
Completed --> Withdrawn Trial primary completion date: Jun 2016 --> Sep 2016
- Keytruda (pembrolizumab) / Merck (MSD), Cotellic (cobimetinib) / Exelixis, Roche, Zelboraf (vemurafenib) / Roche
Enrollment open, PD(L)-1 Biomarker, Metastases: Dose-seeking Study of Pembrolizumab Plus Vemurafenib and Cobimetinib Advanced Melanoma (clinicaltrials.gov) - Jul 28, 2016
P1, N=50, Recruiting, Sponsor: University of Pittsburgh
Trial primary completion date: Jun 2016 --> Sep 2016 Not yet recruiting --> Recruiting
- Young TIL / National Cancer Institute
Trial termination, Metastases: Vemurafenib and White Blood Cell Therapy for Advanced Melanoma (clinicaltrials.gov) - Jul 25, 2016
P1, N=12, Terminated, Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Recruiting Active, not recruiting --> Terminated
- Cotellic (cobimetinib) / Exelixis, Roche, Zelboraf (vemurafenib) / Roche
Trial primary completion date, Metastases: Treatment of a Resistant Disease Using Decitabine Combined With Vemurafenib Plus Cobimetinib (clinicaltrials.gov) - Jul 19, 2016
P1/2, N=38, Recruiting, Sponsor: University of Iowa
Active, not recruiting --> Terminated Trial primary completion date: Jun 2016 --> Jun 2017
- Herceptin (trastuzumab) / Roche, Zelboraf (vemurafenib) / Roche
Enrollment closed, Enrollment change: SHIVA: A Randomized Phase II Trial Comparing Therapy Based on Tumor Molecular Profiling Versus Conventional Therapy in Patients With Refractory Cancer (clinicaltrials.gov) - Jul 13, 2016
P2, N=742, Active, not recruiting, Sponsor: Institut Curie
Trial primary completion date: Jun 2016 --> Jun 2017 Recruiting --> Active, not recruiting | N=1000 --> 742
- | Zelboraf (vemurafenib) / Roche
Trial completion, Trial primary completion date: A Pharmacokinetics (PK) Study to Investigate the Effect of Rifampin on PK of Vemurafenib (Zelboraf) (clinicaltrials.gov) - Jul 5, 2016
P1, N=42, Completed, Sponsor: Hoffmann-La Roche
Recruiting --> Active, not recruiting | N=1000 --> 742 Recruiting --> Completed | Trial primary completion date: May 2016 --> Jan 2016
- Zelboraf (vemurafenib) / Roche
Trial primary completion date: Bioavailability Study of Vemurafenib in Participants With BRAF^V600 Mutation-Positive Malignancies (clinicaltrials.gov) - Jul 5, 2016
P1, N=15, Recruiting, Sponsor: Hoffmann-La Roche
Recruiting --> Completed | Trial primary completion date: May 2016 --> Jan 2016 Trial primary completion date: Jan 2017 --> Apr 2017
- | Keytruda (pembrolizumab) / Merck (MSD), Cotellic (cobimetinib) / Exelixis, Roche, Zelboraf (vemurafenib) / Roche
New P1 trial, PD(L)-1 Biomarker, Metastases: Dose-seeking Study of Pembrolizumab Plus Vemurafenib and Cobimetinib Advanced Melanoma (clinicaltrials.gov) - Jun 29, 2016
P1, N=50, Not yet recruiting, Sponsor: University of Pittsburgh
- CDX-3379 / Celldex
Enrollment closed, Enrollment change: Enhancing Radioiodine Incorporation Into BRAF Mutant Thyroid Cancers With the Combination of Vemurafenib and KTN3379 (clinicaltrials.gov) - Jun 28, 2016
P1, N=7, Active, not recruiting, Sponsor: Kolltan Pharmaceuticals, Inc.
Trial primary completion date: Jan 2017 --> Apr 2017 Recruiting --> Active, not recruiting | N=10 --> 7
- ||| Enrollment change, Tumor mutational burden, BRCA Biomarker, MSi-H Biomarker, PARP Biomarker, PD(L)-1 Biomarker: TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer (clinicaltrials.gov) - Jun 22, 2016
P2, N=1030, Recruiting, Sponsor: American Society of Clinical Oncology
Recruiting --> Active, not recruiting | N=10 --> 7 N=730 --> 1030
- Zelboraf (vemurafenib) / Roche
Trial primary completion date, Metastases: A Study of Vemurafenib (Zelboraf) in Chinese Participants With BRAF V600 Mutation-Positive Unresectable or Metastatic Melanoma (clinicaltrials.gov) - Jun 10, 2016
P1, N=46, Active, not recruiting, Sponsor: Hoffmann-La Roche
N=730 --> 1030 Trial primary completion date: Dec 2016 --> Oct 2013
- | Cotellic (cobimetinib) / Exelixis, Roche, Zelboraf (vemurafenib) / Roche, Tecentriq (atezolizumab) / Roche
Phase classification, Combination therapy, PD(L)-1 Biomarker, IO biomarker, Metastases: A Phase 1b Study of Atezolizumab in Combination With Vemurafenib or Vemurafenib Plus Cobimetinib in Participants With BRAFV600-Mutation Positive Metastatic Melanoma (clinicaltrials.gov) - Jun 2, 2016
P1b, N=70, Recruiting, Sponsor: Genentech, Inc.
Trial primary completion date: Dec 2016 --> Oct 2013 Phase classification: P1 --> P1b
- || Zelboraf (vemurafenib) / Roche
Enrollment closed, Trial primary completion date, Metastases: An Observational Safety Study in Zelboraf (Vemurafenib)-Treated Patients With BRAF-V600 Mutation-Positive Unresectable or Metastatic Melanoma (ZeSS) (clinicaltrials.gov) - Jun 2, 2016
P=N/A, N=339, Active, not recruiting, Sponsor: Hoffmann-La Roche
Phase classification: P1 --> P1b Recruiting --> Active, not recruiting | Trial primary completion date: Mar 2016 --> Jul 2016
- Zelboraf (vemurafenib) / Roche
Enrollment open: A Study to Investigate the Effect of Itraconazole and Rifampin on Pharmacokinetics (PK) of Vemurafenib at Steady State (clinicaltrials.gov) - Jun 2, 2016
P1, N=32, Recruiting, Sponsor: Genentech, Inc.
Recruiting --> Active, not recruiting | Trial primary completion date: Mar 2016 --> Jul 2016 Not yet recruiting --> Recruiting
- Zelboraf (vemurafenib) / Roche, XL888 / Exelixis, Merck (MSD)
Enrollment closed, Trial primary completion date: Study of XL888 With Vemurafenib for Patients With Unresectable BRAF Mutated Stage III/IV Melanoma (clinicaltrials.gov) - May 31, 2016
P1, N=21, Active, not recruiting, Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting | Trial primary completion date: Aug 2016 --> Dec 2016
- Torisel (temsirolimus) / Pfizer, Zelboraf (vemurafenib) / Roche
Enrollment closed, Trial primary completion date, Combination therapy, Metastases: Vemurafenib in Combination With Everolimus or Temsirolimus With Advanced Cancer (clinicaltrials.gov) - May 25, 2016
P1, N=114, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Recruiting --> Active, not recruiting | Trial primary completion date: Aug 2016 --> Dec 2016 Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2017 --> Dec 2018
- Zelboraf (vemurafenib) / Roche
Enrollment closed, Metastases: Study of Vemurafenib, Carboplatin, and Paclitaxel (clinicaltrials.gov) - May 19, 2016
P1, N=96, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2017 --> Dec 2018 Recruiting --> Active, not recruiting
- Xalkori (crizotinib) / Pfizer, Zelboraf (vemurafenib) / Roche
Trial primary completion date, Combination therapy, Metastases: Vemurafenib With Sorafenib Tosylate or Crizotinib in Treating Patients With Advanced Malignancies With BRAF Mutations (clinicaltrials.gov) - May 19, 2016
P1, N=183, Recruiting, Sponsor: M.D. Anderson Cancer Center
Recruiting --> Active, not recruiting Trial primary completion date: Feb 2017 --> Feb 2018
- Cotellic (cobimetinib) / Exelixis, Roche, Zelboraf (vemurafenib) / Roche, Tecentriq (atezolizumab) / Roche
Biomarker, Trial primary completion date, PD(L)-1 Biomarker: Neoadjuvant Vemurafenib + Cobimetinib + Atezolizumab in Melanoma: NEO-VC (clinicaltrials.gov) - May 12, 2016
P2, N=110, Recruiting, Sponsor: University Hospital Tuebingen
Trial primary completion date: Feb 2017 --> Feb 2018 Trial primary completion date: Apr 2016 --> Apr 2017
- ||||| Cotellic (cobimetinib) / Exelixis, Roche, Zelboraf (vemurafenib) / Roche
New P2 trial, Metastases: A Study to Detect V-Raf Murine Sarcoma Viral Oncogene Homolog B1 (BRAF) V600 Mutation on Cell-Free Deoxyribonucleic Acid (cfDNA) From Plasma in Participants With Advanced Melanoma (clinicaltrials.gov) - May 11, 2016
P2, N=208, Recruiting, Sponsor: Hoffmann-La Roche
- Zelboraf (vemurafenib) / Roche
Trial primary completion date: Vemurafenib With Lymphodepletion Plus Adoptive Cell Transfer & High Dose IL-2 Metastatic Melanoma (clinicaltrials.gov) - May 9, 2016
P2, N=30, Recruiting, Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Trial primary completion date: Apr 2016 --> Apr 2017 Trial primary completion date: Aug 2016 --> Dec 2016
- Zelboraf (vemurafenib) / Roche
Trial initiation date, Trial primary completion date: A Study to Investigate the Effect of Itraconazole and Rifampin on Pharmacokinetics (PK) of Vemurafenib at Steady State (clinicaltrials.gov) - May 5, 2016
P1, N=32, Not yet recruiting, Sponsor: Genentech, Inc.
Trial primary completion date: Aug 2016 --> Dec 2016 Initiation date: Dec 2015 --> May 2016 | Trial primary completion date: Jul 2017 --> Jan 2018
- Zelboraf (vemurafenib) / Roche
Trial primary completion date, Metastases: Study of Vemurafenib, Carboplatin, and Paclitaxel (clinicaltrials.gov) - Apr 28, 2016
P1, N=96, Recruiting, Sponsor: M.D. Anderson Cancer Center
Initiation date: Dec 2015 --> May 2016 | Trial primary completion date: Jul 2017 --> Jan 2018 Trial primary completion date: Jul 2017 --> Jul 2018
- Erbitux (cetuximab) / Eli Lilly, Zelboraf (vemurafenib) / Roche
Enrollment change, Combination therapy, Surgery, Metastases: Vemurafenib, Cetuximab, and Irinotecan Hydrochloride in Treating Patients With Solid Tumors That Are Metastatic or That Cannot Be Removed by Surgery (clinicaltrials.gov) - Apr 22, 2016
P1, N=33, Recruiting, Sponsor: M.D. Anderson Cancer Center
Trial primary completion date: Jul 2017 --> Jul 2018 N=77 --> 33
- Zelboraf (vemurafenib) / Roche
Trial primary completion date: BRAF Inhibitor, Vemurafenib, in Patients With Relapsed or Refractory Hairy Cell Leukemia (clinicaltrials.gov) - Apr 7, 2016
P2, N=36, Recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
N=77 --> 33 Trial primary completion date: Oct 2016 --> Oct 2017
- ||||||| Zelboraf (vemurafenib) / Roche
Trial completion, Metastases: A Study of Vemurafenib in Participants With Metastatic Melanoma (clinicaltrials.gov) - Apr 7, 2016
P3, N=3287, Completed, Sponsor: Hoffmann-La Roche
Trial primary completion date: Oct 2016 --> Oct 2017 Active, not recruiting --> Completed
- Cotellic (cobimetinib) / Exelixis, Roche, Zelboraf (vemurafenib) / Roche
Enrollment change, Trial termination, Trial primary completion date, Combination therapy: CoBRIM-B: Phase II Study of Cobimetinib in Combination With Vemurafenib in Active Melanoma Brain Metastases (clinicaltrials.gov) - Apr 7, 2016
P2, N=5, Terminated, Sponsor: Melissa Burgess, MD
Active, not recruiting --> Completed N=72 --> 5 | Recruiting --> Terminated | Trial primary completion date: May 2018 --> Mar 2016; closed due to slow accrual
- || Cotellic (cobimetinib) / Exelixis, Roche, Zelboraf (vemurafenib) / Roche, Tecentriq (atezolizumab) / Roche
Enrollment change, Combination therapy, PD(L)-1 Biomarker, IO biomarker, Metastases: A Phase 1b Study of Atezolizumab in Combination With Vemurafenib or Vemurafenib Plus Cobimetinib in Participants With BRAFV600-Mutation Positive Metastatic Melanoma (clinicaltrials.gov) - Apr 7, 2016
P1, N=70, Recruiting, Sponsor: Genentech, Inc.
N=72 --> 5 | Recruiting --> Terminated | Trial primary completion date: May 2018 --> Mar 2016; closed due to slow accrual N=55 --> 70
- Erbitux (cetuximab) / Eli Lilly, Zelboraf (vemurafenib) / Roche
Enrollment closed, Enrollment change, Metastases: S1406 Phase II Study of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF Mutant Metastatic Colorectal Cancer (clinicaltrials.gov) - Apr 7, 2016
P2, N=106, Active, not recruiting, Sponsor: Southwest Oncology Group
N=55 --> 70 Recruiting --> Active, not recruiting | N=78 --> 106
- | Cotellic (cobimetinib) / Exelixis, Roche, Zelboraf (vemurafenib) / Roche, XL888 / Exelixis, Merck (MSD)
New P1 trial: XL888 + Vemurafenib + Cobimetinib for Unresectable BRAF Mutated Stage III/IV Melanoma (clinicaltrials.gov) - Mar 29, 2016
P1, N=36, Not yet recruiting, Sponsor: H. Lee Moffitt Cancer Center and Research Institute